NCT04983940View on ClinicalTrials.gov

Patient Satisfaction After Switching to Oral Testosterone Undecanoate

PHASE4CompletedINTERVENTIONAL

Enrollment

41

Participants

Timeline

Start Date

June 18, 2021

Primary Completion Date

April 6, 2023

Study Completion Date

April 6, 2023

Conditions

Testosterone Deficiency

Interventions

DRUG

Jatenzo

237 mg soft gel capsule taken twice a day by mouth with food.

Trial Locations (1)

33136

University of Miami, Miami

Sponsors

Collaborators (1)

Clarus Therapeutics, Inc.

All Listed Sponsors

collaborator

Clarus Therapeutics, Inc.

INDUSTRY

lead

University of Miami

OTHER

NCT04983940 - Patient Satisfaction After Switching to Oral Testosterone Undecanoate | Biotech Hunter | Biotech Hunter